ALK Actualización en terapias dirigidas en CPNM ALK+

37 / 48

First line Alectinib (ALEX): CNS and non-CNS efficacy
60
40
30
20
10
0
0
6 Cumulative incidence of
CNS progression, %
50
24 30 12 18
Time, months
Alectinib
Crizotinib
CNS progression in ITT
population
Alectinib
(n=152)
Crizotinib
(n=151)
12-month cumulative
incidence rate, % (95% CI)
9.4 (5.4-14.7) 41.4 (33.2-49.4)
Cause-specific HR (95% CI) 0.16 (0.10-0.28); P<0.001a
Cumulative incidence ofnon-CNS progression, %
Alectinib
Crizotinib
40
30
20
10
0
50
6 12 18
Time, months
24 30 0
Non-CNS progression without
prior CNS prog in
ITT population
Alectinib
(n=152)
Crizotinib
(n=151)
Patients with events, n (%) 36 (24%) 33 (22%)
Cause-specific HR (95% CI) 0.81 (0.49-1.31); P=0.38a
Peters S et al N Eng J Med 2017
IRC-assessed cumulative incidence of
CNS progression
IRC-assessed cumulative incidence of
non-CNS progression without
prior CNS progression